Skip to main content
Journal cover image

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).

Publication ,  Conference
Stinchcombe, TE; Janne, PA; Wang, X; Bertino, EM; Weiss, JM; Bazhenova, L; Gu, L; Lau, CJ; Paweletz, CP; Jaslowski, AJ; Gerstner, GJ ...
Published in: Ann Oncol
October 2018

Duke Scholars

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii522

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L., … Vokes, E. E. (2018). A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). In Ann Oncol (Vol. 29 Suppl 8, p. viii522). England. https://doi.org/10.1093/annonc/mdy292.066
Stinchcombe, T. E., P. A. Janne, X. Wang, E. M. Bertino, J. M. Weiss, L. Bazhenova, L. Gu, et al. “A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).” In Ann Oncol, 29 Suppl 8:viii522, 2018. https://doi.org/10.1093/annonc/mdy292.066.
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, et al. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). In: Ann Oncol. 2018. p. viii522.
Stinchcombe, T. E., et al. “A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).Ann Oncol, vol. 29 Suppl 8, 2018, p. viii522. Pubmed, doi:10.1093/annonc/mdy292.066.
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, Gu L, Lau CJ, Paweletz CP, Jaslowski AJ, Gerstner GJ, Baggstrom MQ, Graziano SL, Bearden J, Vokes EE. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2018. p. viii522.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii522

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis